|Bid||4.9800 x 900|
|Ask||5.0100 x 2900|
|Day's Range||4.7500 - 5.2900|
|52 Week Range||2.5000 - 5.9500|
|Beta (5Y Monthly)||1.37|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 06, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||9.00|
Agenus announced in a tersely worded regulatory filing that chief legal and compliance officer Adam Krauss has served notice that he will be vacating his position, effective this Friday, July 30. Krauss was not a longtime Agenus employee. Prior to that, he served for over four years as chief legal counsel at two different units of healthcare device maker Medtronic.
Conference Call on Monday, August 9, 2021, at 8:30 a.m. ETLEXINGTON, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that it will release its second quarter 2021 financial results before the market opens on Monday, August 9, 2021. Agenus executives will host a conference call and web
Agenus (AGEN) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.